Original articlePharmacokinetics and bioequivalence study of rhein as the main metabolite of Diacerein (cas 13739-02-1)

Add time:09/08/2019    Source:sciencedirect.com

A simple, rapid and fully-validated liquid chromatographic method (RP - HPLC) with fluorescence detection was developed for the analysis of rhein (as the main metabolite of diacerein) in human plasma. The separation was performed using an ODS C18 column with a mobile phase consisted of acetonitrile:methanol:phosphate buffer pH 6.8 and the flow rate was1.0 mL/min. The flourimetric detection was performed at 2 excitation wavelengths ʎex = 440 nm & 338 nm and one emission wavelength at ʎem = 520 nm. The developed method was validated according to Food and Drug administration (FDA) guidelines for bioanalytical method validation. The pharmacokinetic parameters of the test and the reference were determined and the analysis of variance (ANOVA) between parameters of the two brands was calculated. The relative bioavailability was found to be 89%. This method was successfully applied for the routine bioequivalence analysis of diacerein in plasma.

We also recommend Trading Suppliers and Manufacturers of Diacerein (cas 13739-02-1). Pls Click Website Link as below: cas 13739-02-1 suppliers

Prev:Short communicationThe synthesis and photochromism of a 2,2-diaryl-6-styryl-2H-[1]benzopyran: Unexpected palladium-mediated ring-contraction of a 6-bromo-2,2-diaryl-2H-[1]benzopyran
Next:Novel spectrophotometric methods for the determination of Leflunomide and Diacerein (cas 13739-02-1) in binary mixtures)